[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-rhinosinusitis-with-nasal-polypscrswnp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-rhinosinusitis-with-nasal-polypscrswnp":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100592796","tezepelumab-tezspire-regulatory-postmarketing-surveillance-in-korea-100592796",false,"NCT06998095","Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea","Tezepelumab","Inclusion Criteria:\n\n1. Patients who are treated with at least one dose of tezepelumab according to the indication in the locally approved prescribing information\n2. Patients with evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study\n\nExclusion Criteria:\n\n1. Other off-label indications according to the locally approved prescribing information\n2. Current participation in any interventional trial","ALL","12 Years",{"count":19,"type":20},210,"ESTIMATED","OBSERVATIONAL","The objectives of this study are to describe the incidence of adverse events and the effectiveness of tezepelumab in patients receiving tezepelumab as indicated for severe asthma or CRSwNP in South Korea.",[24,25],"Severe Asthma","Chronic Rhinosinusitis With Nasal Polyps(CRSwNP)",[27,28],"severe asthma","Chronic Rhinosinusitis with Nasal Polyps(CRSwNP)","NOT_YET_RECRUITING","2026-06-03",{"date":32,"type":33},"2026-06-04","ACTUAL",{"date":35,"type":20},"2026-11-28",{"date":37,"type":20},"2029-10-31",{"name":39,"class":40},"AstraZeneca","INDUSTRY"]